Another Nail in the Coffin for Anti-Amyloid Development in Alzheimer’s
Roche has pulled the plug on late-phase development for its anti-amyloid MAb crenezumab for...
Roche has pulled the plug on late-phase development for its anti-amyloid MAb crenezumab for...
This time it’s Axovant’s 5HT6 antagonist, intepirdine. The drug was intended as a symptomatic...
UPDATE: The codevelopment agreement between Savant HWP and Humanigen for the US approval of benznidazole is...
Here’s an important follow-up from Zach Brennan at the RAPS website on the FDA’s priority review...
On December 21, 2016, Senators Susan Collins (R-Maine) and Claire McCaskill (D-Missouri), the respective...
This is a MUST READ from Zachary Brennen at RAPS/Regulatory Focus on the review and potential...